



Shionogi Announces Corporate Reorganization and Personnel Reassignment (Effective December 1, 2025)

OSAKA, Japan, October 30, 2025 - Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereafter "SHIONOGI") announces that it will implement the following corporate reorganization and personnel reassignment, effective December 1, 2025.

1. Corporate Reorganization

- In conjunction with the absorption-type merger of the pharmaceutical business of Japan Tobacco Inc., Shionogi will establish the Central Pharmaceutical Research Institute and the Development Business Division under the R&D Supervisory Unit.
- The Venture Alliance Management Office under the R&D Supervisory Unit will be renamed to the Alliance Management Office.

2. Personnel Reassignments

Name	New Position
R&D Supervisory Unit	
Central Pharmaceutical Research Institute	
Makoto Kakutani	Senior Vice President, Central Pharmaceutical Research Institute
Development Business Division	
Takayuki Yamaguchi	Senior Vice President, Development Business Division

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or

obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

For Further Information, Contact:

SHIONOGI Website Inquiry Form: <https://www.shionogi.com/global/en/contact.html>